Switzerland-based chocolate company Nestlé has acquired a portfolio company from a venture capital firm it invests in. Nestlé’s Health Science division, which was set up last year after information about disease-fighting nutrition provided by venture capital firm Inventages Group, has acquired CM&D Pharma, which provides chewing gum, called Fostrap for people with kidney disease, inflammatory bowel disease and colon cancer. 

 UK-based CM&D is part of the portfolio of Nestlé-backed Inventages and comes a month after Nestlé Health Science became operational. In October 2007, CM&D raised £500,000 seed funding from undisclosed private investors. Fasken Martineau acted as legal adviser to CM&D on the sale.  

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?